Ahmed Idbaih Selected Research

Lomustine (CCNU)

1/2020	Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study.
11/2019	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study.
11/2017	Lomustine and Bevacizumab in Progressive Glioblastoma.
6/2017	Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.
3/2016	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
1/2015	Molecular profiling of gliomas: potential therapeutic implications.
10/2013	MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.
1/2013	Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
1/2012	Prophylactic intrathecal chemotherapy in primary CNS lymphoma.
7/2011	Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ahmed Idbaih Research Topics

Disease

85	Neoplasms (Cancer) 09/2022 - 09/2006
53	Glioma (Gliomas) 09/2022 - 09/2006
51	Glioblastoma (Glioblastoma Multiforme) 11/2022 - 11/2007
10	Oligodendroglioma 12/2019 - 08/2008
6	Astrocytoma (Pilocytic Astrocytoma) 11/2019 - 11/2009
4	Langerhans-Cell Histiocytosis (Histiocytosis, Langerhans Cell) 11/2019 - 07/2004
3	Lymphoma (Lymphomas) 03/2022 - 01/2012
3	Histiocytosis 01/2021 - 01/2017
3	Necrosis 12/2019 - 01/2018
3	Carcinogenesis 12/2018 - 09/2008
3	Brain Neoplasms (Brain Tumor) 01/2018 - 01/2013
3	Erdheim-Chester Disease 01/2017 - 09/2014
2	COVID-19 09/2021 - 12/2020
2	Progressive Multifocal Leukoencephalopathy 07/2021 - 06/2021
2	Meningioma (Meningiomas) 01/2020 - 01/2020
2	Diabetes Insipidus 09/2019 - 07/2007
2	Circulating Neoplastic Cells 01/2018 - 01/2015
2	Hyperthermia 10/2017 - 01/2017
1	Infections 09/2021
1	Immune Reconstitution Inflammatory Syndrome 06/2021
1	Chronic Disease (Chronic Diseases) 01/2020
1	Medulloblastoma 01/2020
1	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2020
1	Pituitary Neoplasms (Pituitary Adenoma) 01/2020
1	Spinal Cord Neoplasms (Spinal Cord Tumors) 01/2020

Drug/Important Bio-Agent (IBA)

22	Temozolomide (Temodar)FDA LinkGeneric 11/2022 - 09/2006
18	Biomarkers (Surrogate Marker)IBA 01/2018 - 09/2007
10	Lomustine (CCNU)FDA Link 01/2020 - 07/2011
9	Procarbazine (Matulane)FDA Link 06/2017 - 03/2010
8	Bevacizumab (Avastin)FDA Link 01/2022 - 09/2008
8	Biological ProductsIBA 01/2021 - 11/2009
8	Vincristine (Oncovin)FDA LinkGeneric 06/2017 - 03/2010
7	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2021 - 09/2009
7	DNA (Deoxyribonucleic Acid)IBA 11/2017 - 05/2010
6	VemurafenibIBA 11/2019 - 09/2014
6	Codon (Codons)IBA 01/2017 - 07/2007
6	MethyltransferasesIBA 09/2014 - 09/2006
4	NivolumabIBA 11/2022 - 01/2019
4	5- (2'- naphthyl)- 7- 4- chlorophenyl- (2,3,6,8- tetrahydro)pyrrolo- (3,4- e)(1,4)- diazepine- 6- thioxo- 8- (1H,7H)oneIBA 12/2021 - 03/2016
4	Pharmaceutical PreparationsIBA 01/2020 - 01/2016
4	Proteins (Proteins, Gene)FDA Link 01/2018 - 11/2007
4	alpha-internexinIBA 11/2011 - 05/2008
3	IronIBA 09/2021 - 01/2017
3	Antimitotic AgentsIBA 01/2021 - 12/2015
3	ErbB Receptors (EGF Receptor)IBA 02/2020 - 08/2008
3	Carboplatin (JM8)FDA LinkGeneric 01/2020 - 01/2016
3	Mitogen-Activated Protein KinasesIBA 12/2019 - 11/2009
3	AntibodiesIBA 01/2019 - 10/2015
3	Transcription Factors (Transcription Factor)IBA 01/2018 - 03/2008
3	RNA (Ribonucleic Acid)IBA 01/2018 - 11/2009
3	Histones (Histone)IBA 10/2016 - 01/2014
3	Irinotecan (Camptosar)FDA LinkGeneric 04/2015 - 09/2008
2	Immune Checkpoint InhibitorsIBA 11/2022 - 07/2021
2	GadoliniumIBA 03/2022 - 12/2021
2	Tyrosine Kinase InhibitorsIBA 02/2022 - 09/2008
2	Angiogenesis InhibitorsIBA 01/2022 - 09/2008
2	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2021 - 12/2020
2	Everolimus FDA Link 01/2020 - 01/2015
2	somatostatin receptor 2IBA 01/2020 - 01/2018
2	MicroRNAs (MicroRNA)IBA 12/2018 - 01/2018
2	ATP-Binding Cassette Transporters (ABC Transporters)IBA 07/2018 - 07/2018
2	Adenosine Triphosphate (ATP)IBA 07/2018 - 07/2018
2	Messenger RNA (mRNA)IBA 01/2018 - 11/2010
2	Complement System Proteins (Complement)IBA 09/2014 - 05/2011
2	ParaffinIBA 09/2014 - 04/2008
2	O-(6)-methylguanineIBA 09/2014 - 05/2010
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2014 - 09/2008
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2013 - 09/2008
2	Alkylating AgentsIBA 11/2007 - 09/2006
1	Dihydroxyphenylalanine (Dopa)IBA 09/2022
1	regorafenibIBA 02/2022
1	Immune Checkpoint ProteinsIBA 01/2022
1	Somatotropin Receptors (Growth Hormone Receptor)IBA 01/2022
1	Contrast MediaIBA 12/2021
1	p21-Activated KinasesIBA 12/2021
1	Small Interfering RNA (siRNA)IBA 12/2021
1	ferrocifenIBA 09/2021
1	larotrectinibIBA 01/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021
1	Proteasome InhibitorsIBA 01/2021
1	marizomibIBA 01/2021
1	CyclinsIBA 01/2021
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 12/2020
1	bcl-X ProteinIBA 10/2020
1	epidermal growth factor receptor VIIIIBA 02/2020
1	Octreotide (Sandostatin)FDA LinkGeneric 01/2020
1	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 01/2020
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020

Therapy/Procedure

38	Drug Therapy (Chemotherapy) 09/2021 - 11/2007
28	Therapeutics 02/2021 - 07/2004
17	Radiotherapy 11/2022 - 09/2010
6	Chemoradiotherapy 11/2022 - 05/2011
6	Precision Medicine 01/2022 - 11/2015
3	Artificial Respiration (Mechanical Ventilation) 09/2021 - 11/2017
2	Aftercare (After-Treatment) 01/2020 - 01/2020
2	Molecular Targeted Therapy 11/2015 - 09/2008
1	Immunotherapy 01/2021
1	Combined Modality Therapy 12/2020
1	Adjuvant Chemotherapy 12/2020
1	Re-Irradiation 01/2020